Abbott to address chronic conditions and infectious diseases

Mumbai, August 7, 2021:

Abbott, a global healthcare leader, stated that it is addressing the chronic conditions and infectious diseases through patient-centered medical devices and diagnostics tests that are unlocking real-time data insights -- harnessing data and technology to help people treat and prevent disease.

The company is focusing on innovative technologies that can improve the way clinicians treat people with vascular diseases, irregular heartbeats and diseases of the heart's valves and other structures.

“We are driving a future where medical devices are smaller, faster, connected, predictive and fit seamlessly into people’s lives -- connecting patients and their doctors beyond the four walls of the clinic and enabling them to make accurate, timely and informed health decisions.," stated Payal Agrawal,  GM and country head India & subcontinent -Structural Heart - Abbott.

The company has recently launched the Amplatzer Piccolo Occluder, the world's first medical device that can be implanted in the tiniest babies (weighing as little as 700 gms) using a minimally invasive procedure.

This device is the world’s first minimally invasive medical device for the treatment of a common congenital heart defect occurring in premature babies, patent ductus arteriosus, or PDA.

Patent ductus arteriosus (PDA) is an opening between two blood vessels leading from the heart. The device, which is even smaller than a pea, can be implanted in the tiniest babies (weighing as little as 700 gms) and is only transcatheter device to treat this life-threatening opening in the heart for pre-term babies.

One of the most common congenital heart defects occurring in premature babies, PDA is a potentially life-threatening opening between two blood vessels leading from the heart.

Agrawal added, “Approximately 3.5 million premature babies are born in India each year with a very low birth weight . The incidence of PDA ranges from 15% to 37% in newborn babies weighing less than 1750 gms. Overall, PDA constitutes 5%–10% of all congenital heart defects with a prevalence of “symptomatic” PDA being 0.5/1000 live births.”

Abbott is a global healthcare leader that helps people live more fully at all stages of life. It has the portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. PharmaBiz